# Penumbra, Inc. (PEN) — Stock CV

Penumbra, Inc. is a $12.6B healthcare company. Revenue grew 17.6% over the last year, and it keeps 11¢ of every dollar of sales as profit. It trades at 78.3× earnings — in the cheapest third of its own history.

> Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians.

## Identity

- **Ticker**: PEN
- **Sector**: Healthcare
- **Industry**: Surgical & Medical Instruments & Apparatus
- **Headquarters**: ALAMEDA, CA
- **Employees**: 4 700
- **Website**: https://www.penumbrainc.com
- **Market cap**: $12.6B
- **Last price**: $319.40
- **Financial profile**: Strong

## Vitals (TTM)

- **Revenue**: $1.50B
- **Net income**: $161M
- **Free cash flow**: $216M
- **P/E**: 78.3
- **Revenue growth (YoY)**: 17.6%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 37 |
| Growth | 65 |
| Profitability | 64 |
| Health | 75 |
| Quality | 90 |
| Moat | 40 |

## Qualifications (beginner checklist) — 9 of 10 passed

- [x] Revenue growing — +17.6% YoY
- [x] Profitable — $161M TTM
- [x] Profit growing — +1168.1% YoY
- [x] Generates cash — $216M TTM
- [x] Debt under control — current ratio 5.75
- [x] Established company — $12.6B market cap
- [x] Not printing shares — +9.9% shares over ~5y
- [x] Proven track record — 8/10 profitable years
- [x] Financially stable — Altman Z 18.5 — safe
- [ ] Valuation not extreme — P/E 78.3

## Experience (career milestones)

- **FY2025** — Best year on record: $178M net income
- **FY2023** — Revenue crossed $1B: $1.06B for the year
- **FY2016** — First recorded profitable year: $14.8M net income

## Strengths

- High gross margin (67.8%)
- Revenue growing 17.6% year over year
- High returns on invested capital (ROIC 20.1%)
- Piotroski F-Score 8/9 — fundamentally strong checklist
- Altman Z-Score 18.49 — low bankruptcy-risk zone

## Watch-outs

- Loss-making in 2 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $748M | $5.28M | -$11.7M |
| FY2022 | $847M | -$2.00M | -$75.0M |
| FY2023 | $1.06B | $91.0M | $82.1M |
| FY2024 | $1.19B | $14.0M | $147M |
| FY2025 | $1.40B | $178M | $175M |

---

Source: https://stockcv.com/PEN — derived from company filings; may be delayed or incomplete. Information, not investment advice.